Innate Pharma S.A.
IPHYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5 | $0 | $12 | $21 |
| % Growth | 1,660.9% | -97.8% | -42.4% | – |
| Cost of Goods Sold | $21 | -$29 | $29 | $25 |
| Gross Profit | -$16 | $29 | -$17 | -$3 |
| % Margin | -322.2% | 10,634.8% | -135.5% | -14.6% |
| R&D Expenses | $21 | $23 | $29 | $25 |
| G&A Expenses | $10 | $3 | $9 | $9 |
| SG&A Expenses | $10 | $2 | $10 | $9 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | -$21 | $29 | -$29 | -$25 |
| Operating Expenses | $10 | $55 | $10 | $9 |
| Operating Income | -$25 | -$25 | -$26 | -$12 |
| % Margin | -523.2% | -9,152.9% | -213.1% | -57.2% |
| Other Income/Exp. Net | $4 | $1 | $2 | $3 |
| Pre-Tax Income | -$21 | -$25 | -$25 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21 | -$25 | -$25 | -$9 |
| % Margin | -439.2% | -8,951.8% | -200.6% | -43.3% |
| EPS | -0.25 | -0.3 | -0.31 | -0.11 |
| % Growth | 16.7% | 3.2% | -181.8% | – |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.12 |
| Weighted Avg Shares Out | 85 | 81 | 80 | 81 |
| Weighted Avg Shares Out Dil | 87 | 81 | 81 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $0 | $2 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $2 |
| EBITDA | -$25 | -$21 | -$26 | -$10 |
| % Margin | -515.7% | -7,734.8% | -207.1% | -48.5% |